Key Highlights
- ICMR has licensed the anti-HPV drug candidate SHetA2 to Emcure Pharmaceuticals for further development.
- The therapy aims to treat precancerous cervical lesions without surgery by selectively targeting HPV-infected cells.
- If successful in clinical trials, SHetA2 could become one of the first non-surgical treatments for Stage 0 cervical cancer.
- India reports nearly 80,000 new cervical cancer cases and over 42,000 deaths annually.
- Experts say the drug is promising but stress that it must undergo rigorous clinical trials before becoming available to patients.
ICMR's SHetA2 Could Transform Cervical Cancer Treatment in India
In a major step toward advancing cancer care, the Indian Council of Medical Research (ICMR) has licensed SHetA2, a first-in-class anti-HPV therapeutic candidate, to Emcure Pharmaceuticals for further development.
The experimental therapy has been jointly developed by researchers at ICMR's National Institute of Cancer Prevention and Research (NICPR) and the University of Oklahoma's Stephenson Cancer Center in the United States.
Unlike conventional treatments that rely on surgery, SHetA2 is designed to selectively destroy HPV-induced precancerous and cervical cancer cells while preserving healthy tissue. If clinical trials confirm its safety and effectiveness, the drug could redefine how early-stage cervical disease is treated.
A Potential Non-Surgical Alternative for Stage 0 Cervical Cancer
One of the biggest advantages of SHetA2 is its potential to eliminate the need for surgery in patients diagnosed with Cervical Intraepithelial Neoplasia (CIN)—the precancerous condition that can progress to cervical cancer.
CIN is classified into three stages:
- CIN 1: Mild abnormal cell changes that often resolve naturally.
- CIN 2: Moderate changes with a higher risk of progression.
- CIN 3: Severe precancerous changes that require medical intervention.
Stage 0 cervical cancer, also known as carcinoma in situ, occurs when abnormal cells remain confined to the cervix's surface lining and have not invaded deeper tissues.
Current treatment primarily involves surgical procedures such as removing abnormal cervical tissue to prevent cancer progression. While these interventions are highly effective, they may carry risks, particularly for women who wish to preserve fertility.
If SHetA2 proves successful, it could offer a targeted medical therapy that removes diseased cells while leaving healthy cervical tissue intact.
Why This Breakthrough Matters
Cervical cancer remains one of India's biggest public health challenges despite being largely preventable through HPV vaccination and routine screening.
According to available health data:
- India records nearly 80,000 new cervical cancer cases every year.
- More than 42,000 women die annually from the disease.
- India accounts for nearly one-third of the global cervical cancer burden.
Health experts attribute the high disease burden to limited screening coverage, delayed diagnosis, and unequal access to preventive healthcare across the country.
To strengthen prevention efforts, the Government of India launched a nationwide HPV vaccination programme earlier this year, offering free Gardasil-4 vaccines to approximately 1.15 crore 14-year-old girls.
Experts Call It a Promising Shift in Cancer Care
Medical experts believe SHetA2 represents an important scientific milestone because it reflects a broader shift toward precision medicine, where treatments specifically target diseased cells instead of removing healthy tissue.
According to oncology specialists, a successful targeted therapy could significantly benefit women diagnosed during their reproductive years by reducing the need for invasive procedures that may affect future pregnancies.
The approach also aligns with global efforts to develop minimally invasive cancer treatments with fewer long-term complications.
Clinical Trials Will Determine Its Future
Despite the excitement surrounding SHetA2, researchers caution that the drug is still under development and has not yet been approved for clinical use.
The therapy must now undergo multiple phases of clinical trials to determine:
- Its safety profile.
- The most effective dosage.
- Possible side effects.
- Whether it performs better than current surgical treatments.
Only after successful clinical testing and regulatory approval can SHetA2 become part of standard medical care.
Could SHetA2 Help Treat Other HPV-Related Cancers?
Scientists are also exploring whether the same technology could be applied to other diseases caused by high-risk Human Papillomavirus (HPV).
HPV is associated with several cancers, including:
- Anal cancer
- Penile cancer
- Certain head and neck cancers
If SHetA2 successfully treats HPV-driven cervical disease, researchers may investigate its use in managing other HPV-related precancerous conditions and cancers in the future.
What It Means for Patients
While SHetA2 is not yet available as a treatment, its licensing marks an important milestone in India's cancer research landscape. If future studies confirm its effectiveness, the drug could provide women with a less invasive alternative to surgery, improve fertility preservation, and expand treatment options for early-stage cervical disease.
For now, doctors continue to recommend HPV vaccination, regular cervical screening, and timely medical consultation as the most effective strategies to prevent cervical cancer.
Frequently Asked Questions (FAQs)
What is SHetA2?
SHetA2 is an experimental anti-HPV drug candidate developed by ICMR researchers and the University of Oklahoma to target HPV-induced precancerous and cervical cancer cells while preserving healthy tissue.
Can SHetA2 replace surgery for Stage 0 cervical cancer?
Not yet. The drug shows significant promise as a non-surgical treatment, but it must first prove its safety and effectiveness through clinical trials before it can replace existing surgical procedures.
What is Stage 0 cervical cancer?
Stage 0 cervical cancer, also known as carcinoma in situ, is the earliest stage of cervical cancer where abnormal cells are confined to the surface of the cervix and have not spread into deeper tissues.
Why is SHetA2 considered a breakthrough?
Unlike surgery, SHetA2 aims to selectively destroy HPV-infected abnormal cells while preserving healthy cervical tissue, potentially reducing complications and helping preserve fertility.
Who will develop SHetA2 further?
ICMR has licensed SHetA2 to Emcure Pharmaceuticals, which will lead its further development and clinical evaluation.
Can this drug treat other HPV-related cancers?
Researchers believe the technology may eventually be explored for treating other HPV-associated cancers, including anal, penile, and certain head and neck cancers, although this remains under investigation.
What is the best way to prevent cervical cancer?
HPV vaccination, regular cervical screening, early detection, and timely treatment remain the most effective ways to prevent cervical cancer.












Conversation
Be kind and stay on topic. Comments are moderated; abuse, spam and personal attacks are removed. Report a problem